Company History

A comparison of peak meal glucose levels in healthy volunteers with or without the administration of A Novel Transdermally Delivered Human Insulin.

InsuLife acquired the global IP for Insulin and diabetes medicine formulation from Transdermal Delivery Solutions Corp. (TDSC).

A Comparison of Injected Insulin Replacement Therapy With A Novel Transdermally Delivered Human Insulin Product.

A clinical study on Dermal Cumulative Irritation with the TDS® drug delivery system was conducted by The Langford Institute under Dr. Howard Maibach at Dermatology Research Laboratory in San Francisco.

Several pharmaceutical drugs were formulated and converted to TDS. Development of larger and biological molecules began.

The first patent for the Transdermal Delivery System, TDS®, was awarded.

In the early 1990’s, the CEO of HypoSpray Pharma, Kenneth B. Kirby, began researching ways to improve the safety and efficiency of transdermal drug delivery. He began by investigating which compounds could transmigrate the skin readily and rapidly, without the need to overcome the natural protective barriers of the human skin.